Compare Marvell Technology Inc (MRVL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Marvell Technology (MRVL) trades at $245.28, down 7.74% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $327.86 implying significant upside. The company reported three consecutive quarterly EPS beats, with Q3 2026 expected at $1.1, and projects robust revenue growth, particularly in its custom AI chip business, which is forecast to more than double by fiscal 2028. Despite a net loss in 2025, improving operating cash flow and a strong gross margin of 52.21% highlight underlying operational strength.

The outlook for MRVL is positive, driven by AI-driven demand in data centers and custom silicon deals with hyperscalers like Google, though high valuation multiples (P/E of 88.98) and execution risks in scaling custom chip production pose challenges. Investor sentiment remains bullish, with 83.79% of analysts rating the stock a buy, but volatility near all-time highs and competitive pressures warrant caution.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.